We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two Guidances Focus on ANDA Reconsideration and Viral Safety of Biotech Products
Two Guidances Focus on ANDA Reconsideration and Viral Safety of Biotech Products
In two recently issued documents, the FDA tackled methods for requesting reconsideration of an ANDA decision and provided final guidance on evaluating the viral safety of biotechnology products.